摘要
目的探究蒙药那如-3味丸对普瑞巴林联合神经阻滞治疗神经病理性疼痛(NP)效果的影响。方法选择2022年10月至2023年9月确诊为NP的疼痛科住院患者41例,男20例,女21例,年龄40~80岁,BMI≥18.5 kg/m^(2)。采用随机数字表法将患者分为两组:蒙药那如-3味丸组(观察组,n=20)和常规治疗组(对照组,n=21)。对照组为常规治疗,口服普瑞巴林胶囊联合超声引导下疼痛区域神经阻滞;观察组在常规治疗的基础上增加蒙药那如-3味丸(2 g/10粒),每晚临睡前口服3~5粒,共2周。记录治疗前1 d、治疗后2周、1个月、2个月数字评分量表(NRS)疼痛评分、简化McGill疼痛问卷(SF-MPQ)评分、匹兹堡睡眠质量指数(PSQI)。分别于治疗前1 d、治疗后2周采用ELISA法检测血清IL-6、IL-8、IL-1β、TNF-α浓度。记录治疗期间不良反应的发生情况,如恶心、呕吐、腹胀、心悸、嗜睡和头晕等。结果与治疗前1 d比较,治疗后2周、1个月、2个月两组NRS疼痛评分、SF-MPQ评分、PSQI均明显降低(P<0.05);治疗后2周两组血清IL-6、IL-1β、TNF-α浓度明显降低(P<0.05)。与对照组比较,治疗后2周、1个月、2个月观察组NRS疼痛评分、SF-MPQ评分、PSQI均明显降低(P<0.05);治疗后2周观察组IL-6、IL-1β、TNF-α浓度明显降低(P<0.05)。两组不良反应发生率差异无统计学意义。结论蒙药那如-3味丸联合常规疗法可有效减轻NP患者的疼痛,改善患者的睡眠质量,且可能具有调节神经炎症作用。
Objective To explore the effect of Mongolian medicine Naru-3 pills on the treatment of neuropathic pain(NP)with pregabalin combined with nerve block.Methods Forty-one hospitalized patients in the department of pain medicine diagnosed with NP from October 2022 to September 2023 were selected,including 20 males and 21 females,aged 40-80 years,BMI≥18.5 kg/m^(2).The patients were divided into two groups by random number table method:Mongolian medicine Naru-3 pills group(observation group,n=20)and conventional treatment group(control group,n=21).The control group received conventional treatment:oral pregabalin capsule combined with ultrasound-guided nerve block in pain area.The observation group was added oral administration of Mongolian medicine Naru-3 pills(2 g/10 capsules)on the basis of conventional treatment,taking 3-5 capsules orally before going to bed every night for 2 weeks.The numerical rating scale(NRS)pain score,short-form McGill pain questionnaire(SF-MPQ)score,and Pittsburgh sleep quality index(PSQI)were recorded before treatment and 2 weeks,1 month,and 2 months after the treatment.The serum concentrations of IL-6,IL-8,IL-1β,and TNF-αwere detected by enzyme-linked immunosorbent assay(ELISA)1 day before treatment and 2 weeks after treatment.Occurrence of adverse reactions during treatment such as nausea,vomiting,bloating,palpitations,drowsiness,and dizziness were recorded.Results Compared with 1 day before treatment,NRS pain score,SF-MPQ score,and PSQI were lower in both groups 2 weeks,1 month,and 2 months after the treatment(P<0.05),the serum concentrations of IL-6,IL-1β,and TNF-αwere reduced in both groups 2 weeks after the treatment(P<0.05).Compared with the control group,NRS pain score,SF-MPQ score,and PSQI were lower in the observation group 2 weeks,1 month,and 2 months after the treatment(P<0.05);the serum concentrations of IL-6,IL-1β,and TNF-αwere reduced in the observation group 2 weeks after the treatment(P<0.05).There was no significant difference in the incidence of adverse reactions bet
作者
越娜
澈力木格
李辉
吕亮亮
郎海云
铁植
都义日
YUE Na;CHE Limuge;LI Hui;LYU Liangliang;LANG Haiyun;TIE Zhi;DU Yiri(Department of Anesthesiology,Compass Department of Ordos Central Hospital,Ordos 017000,China)
出处
《临床麻醉学杂志》
CAS
CSCD
北大核心
2024年第10期1068-1072,共5页
Journal of Clinical Anesthesiology
基金
高等学校青年科技英才支持计划(NJYT22020)
内蒙古自治区卫生健康科技计划项目(202201244)
内蒙古医科大学蒙药学“一流学科”引进培育人才科研项目(ylxkyjrc2021-02)。
